On May 22, Kelun-Biotech Biopharmaceutical rose 5.34% at open, trading at 477.8 HKD/share, with trading volume of approximately 5.86 million HKD.

On the news front, the company announced it will present multiple clinical research results at the ASCO Annual Meeting, with two registration studies — TROP2 ADC sacituzumab tirumotecan (sac-TMT) and RET inhibitor lenboretinib — selected for the metastatic non-small cell lung cancer oral presentation session. Phase III data demonstrated that sac-TMT combined with pembrolizumab significantly extended progression-free survival compared to pembrolizumab alone in lung cancer patients.

Additionally, Merck recently confirmed that the globally co-developed sac-TMT achieved both overall survival and progression-free survival primary endpoints in the Phase III TroFuse-005 study for advanced or recurrent endometrial cancer, marking the first ADC to demonstrate dual OS and PFS improvement in this indication. The company also received NMPA approval for IND of its PD-1×VEGF bispecific antibody SKB118 for advanced solid tumors, with multiple R&D milestones continuing to catalyze share price performance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)